<< Back To Search

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05092451
Age 12 - 80
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a combination of existing therapies and new methods to enhance effectiveness.
  • It aims to target the cancer cells more precisely, potentially leading to better results with fewer side effects.
  • Patients will be monitored closely to assess how well the treatment works and to identify any side effects.
  • This study is unique because it combines different treatment strategies that have not been used together before, which may provide new options for patients.
  • Researchers are particularly interested in how this combination can improve the quality of life for patients undergoing treatment.
Overall, this study represents an innovative approach to treating blood cancer, with the hope of providing more effective and personalized care for patients.
Third Opinion AI Generated Synopsis

Trial Summary
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: